医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Community-Acquired Bacterial Pneumonia

2012年09月26日 AM01:59
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/5fxhnt/communityacquired) has announced the addition of Decision Resources, Inc’s new report “Community-Acquired Bacterial Pneumonia” to their offering.

The community-acquired bacterial pneumonia (CABP) market is highly crowded and genericized; nevertheless, it has important unmet needs for new therapies that are active against key drug-resistant pathogens and that can demonstrate efficacy in the moderate to severe CABP population. Although the majority of CABP patients are treated in the outpatient setting, the inpatient setting represents more than half of the CABP market and will be the area of highest commercial growth over the 2010-2020 period. Key drivers of the CABP inpatient segment include the uptake of marketed and emerging antibiotic brands and the anticipated increase in disease severity among hospitalized patients.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– Overview

– Future Positioning of Key Competitors

– Drug Development and Regulatory Hurdles

– Oxazolidinones

– Overview

– Mechanism of Action

– Radezolid

– Macrolides and Related Agents

– Overview

– Mechanism of Action

– Solithromycin

– Quinolones

– Overview

– Mechanism of Action

– Nemonoxacin

– Delafloxacin

– JNJ-Q2

– Zabofloxacin

– Streptogramins

– Overview

– Mechanism of Action

– NXL-103

– 6 Market Outlook

– Appendix A Bibliography Community Acquired Bacterial Pneumonia

– Appendix B Market Forecast Methodology

– Appendix C Experts Interviewed Community Acquired Bacterial Pneumonia

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/5fxhnt/communityacquired

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作